US Patent 7238713 Muscarinic agonists
Patent 7238713 was granted and assigned to Acadia Pharmaceuticals on July, 2007 by the United States Patent and Trademark Office.
All edits
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 16 Sep, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Allan K. Uldam0
Bo Lennart M. Friberg0
Carl-Magnus A. Anderson0
Niels Skjaerbaek0
Tracy A. Spalding0
Edits on 1 Sep, 2023
Golden AI
Edits made to:
Article (+324 characters)
Article
Patent abstract
Compounds and methods are provided for the treatment of disease conditions in which modification of cholinergic, especially muscarinic m1, m4, or both m1 and m4, receptor activity has a beneficial effect. In the method, an effective amount of a compound is administered to a patient in need of such treatment.
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 20 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07238713 Muscarinic agonists US Patent 7238713 Muscarinic agonists
Infobox
Patent Number
072387130
Patent Number
72387130
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
072387130
Date of Patent
July 3, 2007
0Patent Application Number
106231190
Date Filed
July 17, 2003
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 21 Nov, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07238713 Muscarinic agonists
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07238713
Date of patent
July 3, 2007
Patent application number
10623119
Date Filed
July 17, 2003
Patent primary examiner
Find more entities like US Patent 7238713 Muscarinic agonists
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
